Jabez is advancing a focused pipeline of rational, synergistic cancer therapies: beginning with JBZ-001, an oral DHODH inhibitor currently in Phase 1 clinical development.

JBZ-001 is just the beginning of a scalable, clinically grounded development strategy. Our approach is driven by the 3-S model: selecting therapeutics that have seamless administration, scalable manufacturing, and synergize with existing standards of care.